Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 25 | 2021 | 424 | 4.120 |
Why?
|
| Liver Cirrhosis | 6 | 2018 | 82 | 2.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2016 | 29 | 1.150 |
Why?
|
| Anti-Retroviral Agents | 4 | 2020 | 22 | 1.040 |
Why?
|
| Transaminases | 2 | 2015 | 10 | 0.920 |
Why?
|
| Elasticity Imaging Techniques | 3 | 2018 | 12 | 0.630 |
Why?
|
| Anti-HIV Agents | 3 | 2019 | 61 | 0.610 |
Why?
|
| Hepatitis C, Chronic | 2 | 2016 | 77 | 0.590 |
Why?
|
| Fibrosis | 2 | 2021 | 125 | 0.540 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2017 | 4 | 0.520 |
Why?
|
| Hypertension, Portal | 1 | 2017 | 10 | 0.520 |
Why?
|
| Osteonecrosis | 2 | 2007 | 22 | 0.500 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 243 | 0.470 |
Why?
|
| Inflammation | 4 | 2021 | 543 | 0.470 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2019 | 32 | 0.450 |
Why?
|
| HIV-1 | 3 | 2019 | 46 | 0.440 |
Why?
|
| Middle Aged | 19 | 2021 | 12224 | 0.440 |
Why?
|
| Lymphopenia | 2 | 2019 | 11 | 0.430 |
Why?
|
| Adult | 14 | 2020 | 9602 | 0.400 |
Why?
|
| Male | 22 | 2020 | 19784 | 0.400 |
Why?
|
| Humans | 30 | 2021 | 33026 | 0.400 |
Why?
|
| Liver | 6 | 2018 | 492 | 0.390 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 55 | 0.390 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 18 | 0.390 |
Why?
|
| Femur Head Necrosis | 1 | 2013 | 11 | 0.390 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 14 | 0.390 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 10 | 0.390 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 34 | 0.360 |
Why?
|
| Cyclohexanes | 1 | 2012 | 5 | 0.360 |
Why?
|
| Pyrrolidinones | 1 | 2012 | 5 | 0.360 |
Why?
|
| Triazoles | 1 | 2012 | 14 | 0.360 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 57 | 0.350 |
Why?
|
| Female | 19 | 2020 | 20407 | 0.340 |
Why?
|
| Fatty Liver | 3 | 2018 | 66 | 0.330 |
Why?
|
| Biopsy | 4 | 2015 | 245 | 0.320 |
Why?
|
| Mitochondria | 1 | 2012 | 214 | 0.320 |
Why?
|
| Autoantibodies | 3 | 2019 | 50 | 0.300 |
Why?
|
| Adipose Tissue | 1 | 2012 | 351 | 0.300 |
Why?
|
| Interleukin-2 | 1 | 2008 | 33 | 0.270 |
Why?
|
| Viral Load | 5 | 2019 | 73 | 0.270 |
Why?
|
| Immunologic Factors | 1 | 2008 | 51 | 0.270 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2006 | 1 | 0.260 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2006 | 1 | 0.260 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2006 | 2 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2019 | 3462 | 0.240 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 58 | 0.240 |
Why?
|
| Sjogren's Syndrome | 2 | 2017 | 36 | 0.230 |
Why?
|
| Disease Progression | 2 | 2017 | 599 | 0.220 |
Why?
|
| Peptide Fragments | 1 | 2006 | 410 | 0.210 |
Why?
|
| Adolescent | 4 | 2019 | 3646 | 0.200 |
Why?
|
| Aged | 5 | 2020 | 10653 | 0.200 |
Why?
|
| Young Adult | 3 | 2015 | 2747 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2015 | 1855 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 1315 | 0.170 |
Why?
|
| Losartan | 1 | 2021 | 64 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 11 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2019 | 2343 | 0.160 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 27 | 0.150 |
Why?
|
| Virus Replication | 1 | 2019 | 42 | 0.150 |
Why?
|
| Hypertension | 1 | 2006 | 983 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 97 | 0.150 |
Why?
|
| Risk Factors | 4 | 2018 | 4013 | 0.150 |
Why?
|
| Rheology | 1 | 2018 | 32 | 0.140 |
Why?
|
| Histocytochemistry | 2 | 2015 | 30 | 0.140 |
Why?
|
| Smoking | 2 | 2019 | 531 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 1477 | 0.140 |
Why?
|
| Staphylococcal Protein A | 1 | 2017 | 3 | 0.130 |
Why?
|
| Antigen-Antibody Complex | 1 | 2017 | 4 | 0.130 |
Why?
|
| Carotid Arteries | 1 | 2018 | 101 | 0.130 |
Why?
|
| Hepatic Veins | 1 | 2017 | 3 | 0.130 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 6 | 0.130 |
Why?
|
| Endothelium | 1 | 2017 | 7 | 0.130 |
Why?
|
| Pressure | 1 | 2017 | 51 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2019 | 216 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 46 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 1590 | 0.130 |
Why?
|
| Incidence | 2 | 2013 | 1250 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2017 | 45 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 88 | 0.130 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 89 | 0.130 |
Why?
|
| Portal Pressure | 1 | 2016 | 1 | 0.120 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2016 | 4 | 0.120 |
Why?
|
| Maryland | 1 | 2016 | 28 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2016 | 31 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2017 | 83 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 49 | 0.120 |
Why?
|
| Prevalence | 2 | 2016 | 1003 | 0.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2013 | 7 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 308 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 45 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 21 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2018 | 413 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 183 | 0.100 |
Why?
|
| Antibodies | 1 | 2013 | 52 | 0.100 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2013 | 7 | 0.100 |
Why?
|
| Jaundice | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cholestasis | 1 | 2013 | 18 | 0.100 |
Why?
|
| Syndrome | 1 | 2013 | 74 | 0.100 |
Why?
|
| Fatigue | 1 | 2013 | 84 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 17 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 59 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2012 | 82 | 0.090 |
Why?
|
| Muscles | 1 | 2012 | 65 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2018 | 801 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 45 | 0.090 |
Why?
|
| Lipids | 1 | 2012 | 230 | 0.080 |
Why?
|
| Disease Management | 1 | 2012 | 128 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 897 | 0.080 |
Why?
|
| Prognosis | 1 | 2013 | 1549 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 248 | 0.070 |
Why?
|
| Viremia | 1 | 2006 | 5 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 9 | 0.060 |
Why?
|
| Femur Head | 1 | 2007 | 11 | 0.060 |
Why?
|
| Mutation | 1 | 2006 | 499 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2006 | 469 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 2289 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 156 | 0.040 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cholic Acids | 1 | 2020 | 1 | 0.040 |
Why?
|
| Chalcones | 1 | 2020 | 3 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2020 | 2 | 0.040 |
Why?
|
| Uracil | 1 | 2020 | 6 | 0.040 |
Why?
|
| Propionates | 1 | 2020 | 5 | 0.040 |
Why?
|
| Pyridazines | 1 | 2020 | 7 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 136 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 30 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 78 | 0.040 |
Why?
|
| Imidazoles | 1 | 2020 | 92 | 0.040 |
Why?
|
| HIV | 1 | 2019 | 25 | 0.040 |
Why?
|
| Perforin | 1 | 2019 | 2 | 0.040 |
Why?
|
| Granzymes | 1 | 2019 | 6 | 0.040 |
Why?
|
| HLA-B27 Antigen | 1 | 2019 | 8 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 26 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 29 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 122 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 98 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 51 | 0.040 |
Why?
|
| Viscosity | 1 | 2018 | 23 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 1153 | 0.040 |
Why?
|
| Elasticity | 1 | 2018 | 38 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2019 | 202 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 46 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2017 | 37 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 48 | 0.030 |
Why?
|
| Placebos | 1 | 2015 | 63 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 110 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 268 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 397 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 546 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 21 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 14 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 880 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2013 | 59 | 0.030 |
Why?
|
| Computational Biology | 1 | 2013 | 96 | 0.020 |
Why?
|
| Hydrogen | 1 | 2012 | 8 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 2198 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 59 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 92 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 1470 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 290 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 169 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1163 | 0.020 |
Why?
|
| Triglycerides | 1 | 2012 | 230 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 85 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 689 | 0.020 |
Why?
|
| African Americans | 1 | 2016 | 1425 | 0.020 |
Why?
|